Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exposure-response relationship of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis
NL-OMON56478Completed
- Sponsor
- HagaZiekenhuis
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of elexacaftor and ivacaftor in cystic fibrosis (CF) (2 arms), sponsored by HagaZiekenhuis. Primary endpoint: Trough concentration of elexacaftor/tezacaftor/ivacaftor. Started Mar 2024; status: completed.
02
Drugs
elexacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON56478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56478.